Answers are grounded in this paper and cite their sources.
Longitudinal study investigates urinary evDNA as an early biomarker for allograft injury, suggesting its clinical utility.
Extracellular vesicle–bound DNA (evDNA) in urine reflects kidney allograft status. Here, we investigated whether urinary evDNA can serve as an early biomarker of allograft injury, prior to the 1-year protocol biopsy. In this prospective study, 49 kidney transplant recipients were monitored at 1, 3, 6, and 12 months using clinical, blood, and urine data. At the 1-year protocol biopsy, patients were classified as having normal histology or allograft injury based on Banff histopathological criteria and molecular analysis of the biopsy samples. EVs were isolated from urine, and the evDNA copy number was quantified using digital PCR. At 6 months, patients who subsequently developed kidney allograft injury had significantly higher normalized evDNA copy numbers than those with normal histology ( p = 0.0220), while estimated glomerular filtration rate (eGFR) and estimated protein excretion rate (ePER) did not differ. A multivariable model incorporating log-transformed evDNA copy number at 6 months and log-transformed 6-month changes in eGFR and ePER, predicted kidney allograft injury at 1 year with high accuracy (area under the curve of 0.96, sensitivity 83% (95% CI 0.33–1.00), specificity 100% (95% CI 0.88–1.00)). These findings indicate that urinary evDNA is a promising non-invasive biomarker for the early detection of subclinical kidney allograft injury, which could inform timely therapeutic decision-making. Larger, multicentre studies and cost-effectiveness analyses are warranted before integration into routine clinical practice.
No takes yet. Share an insight, caveat, or question.
Vodušek et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: